
## Liping Pan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/561105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Small RNA Profiles of Serum Exosomes Derived From Individuals With Latent and Active Tuberculosis. Frontiers in Microbiology, 2019, 10, 1174.	3.5	62
2	Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB. Journal of Infection, 2015, 70, 367-380.	3.3	56
3	Prevalence and Risk Factors for Latent Tuberculosis Infection among Health Care Workers in China: A Cross-Sectional Study. PLoS ONE, 2013, 8, e66412.	2.5	46
4	Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection. Frontiers in Microbiology, 2018, 9, 1267.	3.5	31
5	Genome-Wide miRNA Analysis Identifies Potential Biomarkers in Distinguishing Tuberculous and Viral Meningitis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 323.	3.9	21
6	Genome-wide transcriptional profiling identifies potential signatures in discriminating active tuberculosis from latent infection. Oncotarget, 2017, 8, 112907-112916.	1.8	19
7	Interferon-Gamma Release Assay Performance of Cerebrospinal Fluid and Peripheral Blood in Tuberculous Meningitis in China. BioMed Research International, 2017, 2017, 1-10.	1.9	16
8	Proteomic profiling for plasma biomarkers of tuberculosis progression. Molecular Medicine Reports, 2018, 18, 1551-1559.	2.4	16
9	Use of T-SPOT.TB for the diagnosis of unconventional pleural tuberculosis is superior to ADA in high prevalence areas: aÂprospective analysis of 601 cases. BMC Infectious Diseases, 2021, 21, 4.	2.9	16
10	Evaluation of digital PCR assay in detection of M.tuberculosis IS6110 and IS1081 in tuberculosis patients plasma. BMC Infectious Diseases, 2020, 20, 657.	2.9	14
11	Diagnostic performance of interferon-γ release assay for lymph node tuberculosis. Diagnostic Microbiology and Infectious Disease, 2016, 85, 56-60.	1.8	13
12	Application of the CRISPRi system to repress sepF expression in Mycobacterium smegmatis. Infection, Genetics and Evolution, 2019, 72, 183-190.	2.3	13
13	Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection. Tuberculosis, 2019, 118, 101861.	1.9	13
14	A proteomics approach to the identification of plasma biomarkers for latent tuberculosis infection. Diagnostic Microbiology and Infectious Disease, 2014, 79, 432-437.	1.8	12
15	Hsp16.3 of mycobacterium tuberculosis in exosomes as a biomarker of tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2427-2430.	2.9	10
16	A Two-Way Proteome Microarray Strategy to Identify Novel Mycobacterium tuberculosis-Human Interactors. Frontiers in Cellular and Infection Microbiology, 2019, 9, 65.	3.9	4
17	Labelâ€Free Quantitative Proteomics Identifies Novel Biomarkers for Distinguishing Tuberculosis Pleural Effusion from Malignant Pleural Effusion. Proteomics - Clinical Applications, 2020, 14, 1900001.	1.6	4
18	Analysis of drug resistance and mutation profiles in <i>Mycobacterium tuberculosis</i> isolates in a surveillance site in Beijing, China. Journal of International Medical Research, 2021, 49, 030006052098493.	1.0	3

#	Article	IF	CITATIONS
19	Diagnostic Performance of a Novel CXCL10 mRNA Release Assay for Mycobacterium tuberculosis Infection. Frontiers in Microbiology, 2022, 13, 825413.	3.5	2
20	Rapid Detection of Mycobacterium tuberculosis in Pleural Fluid Using Resuscitation-Promoting Factor-Based Thin Layer Agar Culture Method. Frontiers in Microbiology, 2022, 13, 803521.	3.5	0